As of Jun 22
| -0.05 / -0.27%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 24.00, with a high estimate of 51.00 and a low estimate of 17.00. The median estimate represents a +28.69% increase from the last price of 18.65.
The current consensus among 8 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.